Menopausal hormone therapy continuation after negative endometrial biopsy
Continuation of systemic estrogen plus an adequate progestogen regimen is appropriate after a normal (negative) endometrial biopsy performed for evaluation of unscheduled bleeding, with short-interval reassessment. [1]
After a normal endometrial biopsy, reassurance and continued management with progestogen optimization for 3 months are recommended. [1]
Required condition for continuation
Continuation should include endometrial protection with a progestogen for people with an intact uterus receiving systemic estrogen therapy. [2]
Regimen-specific implications
The estradiol transdermal patch can be continued when adequate progestogen coverage is maintained. [2]
Progesterone should be continued as part of the estrogen–progestogen regimen after the negative biopsy. [1]
Testosterone therapy does not replace progestogen for endometrial protection in systemic menopausal hormone therapy regimens. [2]
What to do immediately after the negative biopsy
HRT should be continued with adjustments to the progestogen regimen to reduce recurrence of unscheduled bleeding. [1]
Reassurance for 3 months should be provided after a normal endometrial biopsy. [1]
Monitoring and trigger points for re-evaluation
Re-evaluation should be pursued if unscheduled bleeding persists or worsens despite the post-biopsy management period. [1]
If bleeding continues after the initial reassessment interval, urgent endometrial assessment is recommended within the pathway used for persistent or heavy bleeding on HRT. [1]
Safety considerations and escalation criteria
Persistent unscheduled bleeding while on menopausal hormone therapy warrants evaluation to rule out pelvic pathology, especially endometrial hyperplasia and cancer. [3]
An endometrial biopsy negative result should not stop further workup when clinical bleeding persists. [3]
Common clinical error to avoid
Discontinuing or under-dosing the progestogen while continuing systemic estrogen should be avoided because it removes endometrial protection and increases endometrial risk. [2]
Treatment goal
The goal after a negative biopsy is maintenance of systemic symptom control while ensuring adequate endometrial protection and reassessment of recurrent or persistent unscheduled bleeding. [1]